DocWire News Editors

DocwireNews

Icosapent ethyl was associated with a more significant reduction in first, subsequent, and total ischemic events in patients at high cardiovascular risk who are taking statins than initially thought, results from a study presented at the American College of Cardiology Annual Scientific Session in New Orleans.
Researchers for this analysis of the previously reported results of the <a href="https://proddocwire.wpengine.com/conference-coverage/icosapent-ethyl-reduces-cv-events/">REDUCE-IT</a> trial, which included 8,179 patients randomly assigned to <a href="https://proddocwire.wpengine.com/docwire-pick/cardiology-picks/eric-j-velazquez-md-practical-implications-for-pioneer-hf/">icosapent ethyl</a> 4 g daily or to placebo in patients with established cardiovascular disease (about 70% of enrollees), diabetes, elevated triglycerides and elevated LDL-C levels, focused specifically on the effect of the therapy on first and other events. The research team led by Deepak Bhatt, MD, of MPH, executive director of interventional cardiovascular programs at <a href="https://www.brighamandwomens.org/">Brigham and Women’s Hospital</a>, and professor of medicine at Harvard Medical School, used multiple validated statistical models (negative binomial regression, Andersen-Gill, Wei-Lin-Weissfeld with Li and Lagakos modification, and joint-frailty) to examine the different study categories of events. Patients were followed for a media follow-up of 4.9 years.
Even More Efficacious
The study results showed a significant decrease in the total number of endpoint events (61 vs. 89 per 1,000 patient years for icosapent ethyl compared to placebo, respectively; RR=0.70; 95% CI, 0.62 to 0.78; P&lt;0.0001). The results also showed a significant decrease in the key secondary endpoints compared to placebo (P=0.0000006) at five years. Icosapent ethyl also reduced each individual component of the primary endpoint, as well as key secondary endpoint events (32 vs. 44 per 1,000 patient years for icosapent ethyl compared to placebo, respectively; RR=0.70; 95% CI, 0.63 to 0.82; P&lt;0.0001).
The analysis identified 1,606 first events in the patient population (55%), and 1,303 subsequent events (45%). Patients taking icosapent ethyl saw a nearly 25% reduction in first events, a 32% reduction in second events, a 31% reduction in third events, and almost half as many (48%) fourth or more events, according to the analysis.
“In looking at the totality of events—not just the first ones, but subsequent ones too—we see that the drug provides even greater reductions in ischemic events, Dr. Bhatt said in a press release. “By looking only at first events, we underestimate the true underlying treatment benefit offered. From a patient’s perspective certainly, and from a physician’s point of view, icosapent ethyl’s impact on total events is what matters most.”
“With this drug, we are not only preventing that first heart attack but potentially the second stroke and maybe that third fatal event,” Bhatt said. “Prevention of such subsequent cardiovascular events could improve patient outcomes and quality of life and may lower the total cost burden of medical care.”
To read more DocWire News coverage of ACC.19, <a href="https://proddocwire.wpengine.com/conference-coverage/american-college-of-cardiology-2019/">click here</a>.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Icosapent Ethyl Reduces First, Repeat, and Total Cardiovascular Events

ACC 2019 Conference

Icosapent ethyl was associated with a more significant reduction in first, subsequent, and total ischemic events in patients at high cardiovascular risk who are taking statins ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe